Patient characteristics and utilization patterns of romosozumab in routine clinical practice: a European, multi-country, non-interventional study (PRIME)

Study identification

• EU PAS number:
  EUPAS1000000343
• Study ID:
  1000000343
• Official title and acronym:
  Patient characteristics and utilization patterns of romosozumab in routine clinical practice: a European, multi-country, non-interventional study (PRIME)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  Germany

  Greece

  Italy

  Spain

  Sweden

  Switzerland

  United Kingdom
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual: 29/07/2024

Study start date

Planned: 25/03/2025

Actual: 02/04/2025

Date of final study report

Planned: 04/01/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

UCB Biopharma SRL

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable